3-Fluoro-5-((7-(methylthio)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile
[CAS# 1672665-69-8]

Identification

• Classification: Organic raw materials >> Organic fluorine compound >> Fluorobenzonitrile series
• Name: 3-Fluoro-5-((7-(methylthio)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile
• Molecular Formula: C₁₇H₁₂FNO₂S
• Molecular Weight: 313.35
• CAS Registry Number: 1672665-69-8
• SMILES: CSC1=C2C(=C(C=C1)OC3=CC(=CC(=C3)C#N)F)CCC2=O

Properties

• Density: 1.4±0.1 g/cm³, Calc.^*
• Index of Refraction: 1.647, Calc.^*
• Boiling Point: 447.2±45.0 ºC (760 mmHg), Calc.^*
• Flash Point: 224.2±28.7 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07 Warning
• Hazard Statements: H302-H315-H319-H335
• Precautionary Statements: P261-P280-P301+P312-P302+P352-P305+P351+P338

Discovory and Applicatios

3-Fluoro-5-((7-(methylthio)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile is a synthetic compound recognized for its role in medicinal chemistry, specifically in the development of kinase inhibitors. This molecule was initially identified through efforts to create small-molecule inhibitors targeting dysregulated kinases in cancer and inflammatory diseases. The incorporation of the fluoro-benzonitrile moiety and methylthio substituent on the indanone ring contributes to enhanced receptor binding and increased metabolic resilience.

The synthesis process typically involves nucleophilic aromatic substitution and thiolation reactions to introduce the methylthio group. The fluoro-benzonitrile component is strategically coupled to the indanone backbone via etherification. This modular synthetic approach allows for fine-tuning of the molecule’s electronic properties, improving selectivity for kinase targets.

Applications of 3-fluoro-5-((7-(methylthio)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile are prominent in oncology research, where it serves as a lead structure for developing kinase inhibitors aimed at modulating signaling pathways involved in tumor growth and proliferation. Its structural stability and favorable pharmacokinetic properties have made it a valuable asset in preclinical studies.

Current research is exploring the optimization of this compound to enhance its potency and selectivity further. The development of derivatives and analogs is ongoing, with the goal of expanding the therapeutic potential to other diseases involving kinase dysregulation.